A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Pediatrix Medical Group, Inc. MD
Weak broader-coverage candidate · Pediatrix Medical Group, Inc.
On FrontierLab's discovery record since 2026-06-29 (7 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-08), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 0.5% |
|---|---|
| Gross margin | 25.9% |
| Gross profits / assets | 0.24 |
| Rule of 40 | 12.1 |
| Net margin | 11.6% |
| Cash runway (months) | — |
| PEG | 0.2 |
| Price / sales | 1.1 |
Quality checklist
- ✗ Revenue growth — 0.5% (pass ≥ 20%)
- ~ Gross profits / assets — 0.24 (pass ≥ 0.33)
- ✗ Gross margin — 25.9% (pass ≥ 60%)
- ✓ Cash generation
- ✓ Share dilution — -6.3%
Fundamentals — snapshot as of 2026-08-08
| Stage | Established |
|---|---|
| Share issuance (YoY) | -6.3% · buying back shares |
| Moat | — |
| TAM | — |
| P/E (trailing) | 13 |
| EPS (trailing) | $2.09 |
| Burn multiple | — |
| Gross-margin trend (pts) | 1.5 |
| Cash / assets | 0.19 |
| Net debt / EBITDA | 1.2 |
| Statements as of | Q2 FY2026 · filed 2026-08-04 |
Momentum context — a snapshot from 2026-08-08, not current
| Price at surface | $27.08 (as of 2026-08-08) |
|---|---|
| 52-week range | $14.05 – $27.94 |
| % off 52-wk high | -3.1% |
| RSI (14) | 59 |
| Relative volume | 0.9× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-08 (end-of-day). How grades are computed →